---
title: "Huahaipharm's subsidiary Huahai Jiancheng passes on-site inspection by the US FDA"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/256526703.md"
description: "Huahaipharm's subsidiary Huahai Jiancheng underwent an on-site inspection by the U.S. FDA from July 14 to 18, 2025. The inspection included the factory's quality management system and the raw material drug Gabapentin. According to information from the FDA's official website, Huahai Jiancheng's production facility meets U.S. drug CGMP requirements and successfully passed this inspection"
datetime: "2025-09-09T09:48:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/256526703.md)
  - [en](https://longbridge.com/en/news/256526703.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/256526703.md)
---

# Huahaipharm's subsidiary Huahai Jiancheng passes on-site inspection by the US FDA

According to the Zhitong Finance APP, Huahai Pharmaceutical (600521.SH) announced that its subsidiary Zhejiang Huahai Jiancheng Pharmaceutical Co., Ltd. (hereinafter referred to as "Huahai Jiancheng") underwent a pre-approval inspection by the U.S. Food and Drug Administration (hereinafter referred to as "FDA") from July 14 to July 18, 2025. The inspection covered the overall quality management system of the factory and the active pharmaceutical ingredient Gabapentin. Recently, the company learned through the OII office database on the FDA's official website that the Huahai Jiancheng production base meets the U.S. drug CGMP (Current Good Manufacturing Practice) requirements and passed this pre-approval inspection

### Related Stocks

- [600521.CN](https://longbridge.com/en/quote/600521.CN.md)

## Related News & Research

- [Barnes & Noble CEO is fine with stocking AI-written books — if they're labeled. The internet had thoughts.](https://longbridge.com/en/news/287084103.md)
- [Investeringsforeningen Nykredit Invest Balance suspender handel med udvalgte afdelinger](https://longbridge.com/en/news/286877547.md)
- [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md)
- [ZAWYA: KIB Group, represented by KIB Invest, acts as Joint Lead Manager in landmark $700mln Sukuk issuance by First Abu Dhabi Bank](https://longbridge.com/en/news/287054139.md)
- [Release according to article 135 section 2 BörseG](https://longbridge.com/en/news/286754366.md)